MVA Members

Sinntaxis AB

Biotech Companies

Sinntaxis AB – a first in class medical therapy that helps the brain to recover after stroke. Sinntaxis is developing a first in class post-acute treatment to enhance the recovery of brain functions after stroke, based on SIN020, a repositioned, phase II ready drug candidate. Stroke, afflicting 14 million persons each year worldwide, is a leading cause of life-long adult disability resulting in major health care costs globally, e.g. 35 billion USD in the US (2019). Today there are no pharmaceutical post-acute stroke treatments available to treat this major medical need. Sinntaxis aims initially to carry through a clinical proof of concept study in stroke recovery